卡博替尼联合阿替利珠单抗治疗转移性去势抵抗性前列腺癌:多中心、开放标签、1b期试验COSMIC-021扩展队列结果
COSMIC-021是一项多中心开放标签1b期研究,扩展队列6纳入132例新型内分泌治疗后进展的转移性去势抵抗性前列腺癌患者,接受卡博替尼40 mg每日口服联合阿替利珠单抗1200 mg每3周静脉给药。客观缓解率为23%(95% CI 17-32),3-4级治疗相关不良事件发生率为55%,1例5级治疗相关不良事件(脱水)。
要点
- 客观缓解率23%(95% CI 17-32),含3例(2%)确认完全缓解和28例(21%)确认部分缓解。
- 72例(55%)发生3-4级治疗相关不良事件,最常见为肺栓塞(8%)、腹泻(7%)、乏力(7%)和高血压(7%)。
- 1例5级治疗相关不良事件(脱水),28例(21%)因治疗相关不良事件停用任一研究药物。
核心结论
- 卡博替尼联合阿替利珠单抗在新型内分泌治疗后转移性去势抵抗性前列腺癌患者中显示出有前景的抗肿瘤活性和可接受的安全性,支持进一步评估该联合方案。
研究设计与样本
- COSMIC-021为正在进行的多中心、开放标签、1b期研究,含剂量递增阶段和肿瘤特异性扩展阶段。
- 扩展队列6在法国、意大利、荷兰、西班牙和美国的42个癌症研究中心入组转移性去势抵抗性前列腺癌患者。
- 入组标准为年龄≥18岁、既往接受恩扎卢胺或阿比拉酮或两者治疗后出现影像学软组织进展、按RECIST 1.1可测量软组织病灶、ECOG体能状态0或1。
- 患者接受卡博替尼40 mg每日口服联合阿替利珠单抗1200 mg每3周静脉给药,治疗持续至疾病进展或不可接受毒性。
- 2018年4月24日至2020年8月31日共入组132例患者并接受至少一剂研究治疗,所有入组患者均评估疗效和安全性。
主要发现
- 数据截止2021年2月19日,中位随访时间15.2个月(IQR 9.6-21.7)。
- 客观缓解率(研究者按RECIST 1.1评估)为23%(95% CI 17-32;132例中31例)。
- 3例(2%)确认完全缓解,28例(21%)确认部分缓解。
- 72例(55%)发生3-4级治疗相关不良事件,最常见为肺栓塞11例(8%)、腹泻9例(7%)、乏力9例(7%)和高血压9例(7%)。
- 1例5级治疗相关不良事件(脱水);74例(56%)发生任何因果关系的严重不良事件;28例(21%)因治疗相关不良事件停用任一研究药物。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with metastatic castration-resistant prostate cancer have few treatment options after novel hormonal therapy (eg, abiraterone or enzalutamide). We aimed to evaluate cabozantinib, a tyrosine kinase inhibitor with immunomodulatory properties, in combination with the PD-L1 inhibitor atezolizumab in metastatic castration-resistant prostate cancer. METHODS: COSMIC-021 is an ongoing, multicentre, open-label, phase 1b study with a dose-escalation stage followed by tumour-specific expansion stages. Expansion cohort 6 in metastatic castration-resistant prostate cancer was enrolled at 42 cancer research centres in France, Italy, the Netherlands, Spain, and the USA. Eligible patients were aged 18 years or older and had metastatic castration-resistant prostate cancer with radiographic soft tissue progression following treatment with either enzalutamide or abiraterone, or both; measurable soft tissue disease per Response Evaluation Criteria In Solid Tumours (RECIST) version 1.1; and an Eastern Cooperative Oncology Group performance status of 0 or 1. Patients received oral cabozantinib 40 mg per day and intravenous atezolizumab 1200 mg once every 3 weeks. Study treatment continued until progressive disease or unacceptable toxicity. All enrolled patients were assessed for efficacy and safety. The primary endpoint was objective response rate per RECIST version 1.1 as assessed by the investigator. This study is registered with ClinicalTrials.gov, NCT03170960. FINDINGS: Between April 24, 2018, and Aug 31, 2020, 132 patients were enrolled and received at least one dose of study treatment. At data cutoff (Feb 19, 2021), median duration of follow-up was 15·2 months (IQR 9·6-21·7). Objective response rate was 23% (95% CI 17-32; 31 of 132 patients), with three (2%) confirmed complete responses and 28 (21%) confirmed partial responses. 72 (55%) of 132 patients had grade 3-4 treatment-related adverse events, with the most common being pulmonary embolism (11 [8%] patients), diarrhoea (nine [7%]), fatigue (nine [7%]), and hypertension (nine [7%]). There was one grade 5 treatment-related adverse event (dehydration). 74 (56%) of 132 patients had serious adverse events of any causality. 28 (21%) of 132 patients had treatment-related adverse events leading to discontinuation of either study drug. INTERPRETATION: Cabozantinib plus atezolizumab showed promising antitumour activity in patients with metastatic castration-resistant prostate cancer after novel hormonal therapy with an acceptable safety profile, supporting further evaluation of this combination. FUNDING: Exelixis.
引用
- Agarwal N, McGregor B, Maughan BL, et al. Cabozantinib in combination with atezolizumab in patients with metastatic castration-resistant prostate cancer: results from an expansion cohort of a multicentre, open-label, phase 1b trial (COSMIC-021). Lancet Oncol. 2022. PMID: 35690072. doi:10.1016/S1470-2045(22)00278-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。